Pixabay/Michal Jarmoluk
22 January 2021
New research by University of Birmingham scientists has highlighted the potential of low molecular weight dextran-sulphate (ILB) in treating fibrotic diseases – such as open angle glaucoma.
The study, which was published in npj Regenerative Medicine, found that ILB normalised matrix deposition and lowered IOP in a pre-clinical model of glaucoma.
The researchers found that daily subcutaneous injections of ILB reduced extracellular matrix levels within the eye’s main drainage site as well as preventing the degeneration of retinal neurons.
They determined that ILB has multimodal actions across many genes that resolve inflammatory and fibrotic cell processes.
“Our studies provide proof of concept that ILB has potential as a novel disease-modifying therapy for the treatment of POAG and other acute and chronic fibroproliferative conditions,” the study authors concluded.
The study, which was published in npj Regenerative Medicine, found that ILB normalised matrix deposition and lowered IOP in a pre-clinical model of glaucoma.
The researchers found that daily subcutaneous injections of ILB reduced extracellular matrix levels within the eye’s main drainage site as well as preventing the degeneration of retinal neurons.
They determined that ILB has multimodal actions across many genes that resolve inflammatory and fibrotic cell processes.
“Our studies provide proof of concept that ILB has potential as a novel disease-modifying therapy for the treatment of POAG and other acute and chronic fibroproliferative conditions,” the study authors concluded.
Comments (0)
You must be logged in to join the discussion. Log in